Orthocell’s plans to broaden its commercial footprint in existing and new markets drove the company’s share price up 13.8% this week, according to a special report in Stockhead.
The rise followed news of Orthocell plans to accelerate efforts to enter several key markets across CY25 including Thailand, Canada, the UK, Brazil and European Union, building on a third quarter of record revenue.
Here’s an excerpt:
“Perth-headquartered Orthocell was a hero of the ASX healthcare sector in 2024. The company is up more than 265% in the past year and ~20% over the past month. Orthocell sits among the top five performing ASX healthcare stocks of the past year.”